

## Management Change

**Melbourne, Australia – 30 October 2024:** Adherium Limited (ASX:ADR).

Following a review of Adherium’s commercialisation opportunities, together with an assessment of the skills and experience required to most efficiently and effectively achieve success, the Company announces a Management change.

Dr Paul Mastoridis was employed for an initial twelve-month term as CEO. The company and Dr Mastoridis have not been able to agree terms to enable him to continue in his role and his employment with the company will end on January 7 2025. Until then, Dr Mastoridis will be on ‘gardening leave’. The company is grateful that Dr Mastoridis stepped into the CEO role when asked and wishes him well in his future endeavours.

The Company will conduct a formal search for a replacement CEO and has retained Mr Simon Bartholomew of Bartholomew Advisors for this purpose. In the interim, the business will be managed by the Adherium Executive Committee, which is comprised of members of the executive management team and Board.

Leadership transitions can create a degree of uncertainty, but we are confident that Adherium’s strategic direction and momentum will continue unabated. With the experienced guidance of the Board and our dedicated executive management team, we remain fully committed to advancing our commercial initiatives and seizing new opportunities. We don't expect any delays to the progress we are making and we look forward to continuing to deliver innovative health solutions, maintaining our focus on growth, and fostering sustainable value for our stakeholders.

**This ASX announcement was approved and authorised for release by the Board of Adherium.**

Enquiries:

Lou Panaccio

Chair

Adherium Limited

[investors@adherium.com](mailto:investors@adherium.com)

*About Adherium Adherium Limited (ASX: ADR) is a digital health company providing solutions for improving patient treatment with remote monitoring and data solutions. Its Hailie® system is transforming management of chronic respiratory conditions, especially asthma and chronic obstructive pulmonary disease. Hailie improves patient health through better adherence and self-management while enabling doctors to be paid for remote work and saving costs across health systems by avoiding hospital admissions. Adherium’s clinically proven sensors, app and powerful data platform provide remote, real-time, personalised information to patients and clinicians. Adherium is increasing sales in US and other markets by pursuing partnerships with major hospital systems, medical groups and insurers. For more information, visit <https://www.adherium.com/>*